Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: locogringo who wrote (1223819)	4/23/2020 1:59:22 PM
From: sylvester80	Respond to of 1578618

BREAKING: AFTER HYDROXYCHLOROQUINE DEADLY STUDY, NOW COMES GILEAD'S REMDESIVIR FLOPPED IN TRIAL finance.yahoo.com Stocks rapidly pared earlier gains Thursday afternoon after the Financial Times reported that a hopeful coronavirus treatment from Gilead ( GILD) flopped in a trial. The study for Gilead’s antiviral drug remdesivir produced results that did not give meaningful conclusions on its efficacy, and the study ended due to low enrollment, according to the report. Last week, a report that provided upbeat anecdotal data on remdesivir’s effectiveness in treating patients with COVID-19 in Chicago had sent stocks on a tear. Investors also continued to digest Thursday’s initial unemployment claims report, which showed that millions more individuals filed for unemployment benefits last week.